30 results about "Neuroectoderm" patented technology

The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumor cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized LK26 specific antibodies. Additionally, the invention provides methods of treating cancer using LK26 specific antibodies.

This invention relates to the production of populations of Smooth Muscle Cells (SMCs) of specific embryonic lineages, such as neuroectodermal and mesodermal SMCs. Pluripotent stem cells are cultured in one or more lineage induction media to produce progenitor cells of a defined embryonic lineage, which are then cultured in an SMC induction medium to produce a population of SMCs of the embryonic lineage. Populations of SMCs of defined lineages may be useful, for example, in accurately modelling vascular disease.

A transcription factor both necessary and sufficient for human neuroectoderm specification, Pax6, as well as applications thereof, is disclosed.

The invention discloses a method for preparing neural stem cells, which comprises a step of inductively culturing P19 cells in N2B27 culture medium to obtain a cell group containing neural stem cells above 94%. The method can culture the P19 cells in an environment without blood serum and retinoic acid, thus suppressing the interference of the blood serum with complex components and preventing the obtained neural stem cells from being transformed posteriorly by retinoic acid. Moreover, the method can directly transform pluripotent stem cells to neutral stem cells without resulting in selective cell apoptosis. The neutral stem cells obtained by the invention have anterior neutral plate characteristics and totipotency, and can well simulate the neurogenesis process in body. Accordingly, theneural stem cells can be used as the research model for analyzing neural induction and neural differentiation process from epiblast to neuroderm, thus providing an ideal path for researching development of embryo after nidation.

The invention belongs to the technical field of bioengineering, and discloses a method for obtaining monkey haploid neural stem cells. The haploid embryonic stem cells are treated with 0.05% trypsin / EDTA for optimized cultivation on the basis of the original ordinary monkey stem cell culture medium. Cloned into a single-cell state, cultured in suspension with EB medium to form embryoid body spheres; from the first day of differentiation, the medium should be added with ROCK inhibitor Y-27632 to inhibit cell apoptosis; on the fifth day of EB The culture medium was changed to neural induction medium; the EB balls that initially formed the neuroectoderm were planted in a petri dish with substrate gel, and neural induction medium was added for differentiation; neural rosettes were picked and planted in 30 μg / ml polyornithine and 3 μg / ml laminin in the culture dish; after 14 days of culture, flow cytometry was performed to sort haploid cells. The present invention realizes for the first time that monkey haploid neural stem cells are obtained in vitro, and have the ability to differentiate toward the downstream direction of nerves.

The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into neural crest, cranial placode or non-neuro ectoderm precursors, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative and pituitary disorders.

Described herein are methods, compositions, and kits for directed differentiation of human pluripotent stem cells into caudal lateral epiblasts, posterior neuroectoderm or posterior neuroepithelium, or motor neurons having specified HOX gene expression pattern mirroring a desired position along the rostral-caudal axis during hindbrain and spinal cord development. Also described are isolated populations of cells including caudal lateral epiblasts, posterior neuroectoderm, posterior neuroepithelium, or motor neurons having a HOX gene expression pattern specified to correspond to the HOX gene expression pattern associated with a desired rostral-caudal axis position.